Lovax OD 300 Tablet ER contains Oxcarbazepine 300 mg as its active ingredient and is an extended-release formulation designed for the management of epilepsy. Oxcarbazepine is an antiepileptic drug that stabilizes hyperexcited neural membranes, inhibits repetitive neuronal firing, and diminishes propagation of synaptic impulses. It is primarily indicated for the treatment of partial seizures with or without secondary generalization in adults and children aged 6 years and above. The extended-release formulation allows for once-daily dosing, improving patient compliance by maintaining steady plasma drug concentrations. Lovax OD 300 Tablet ER acts by blocking voltage-sensitive sodium channels, thereby reducing neuronal excitability and seizure activity. It may also have effects on calcium channels and potassium currents, contributing to its anticonvulsant properties. Common adverse effects include dizziness, somnolence, headache, nausea, and hyponatremia, which should be monitored during therapy. Caution is advised in patients with a history of hypersensitivity to carbamazepine or oxcarbazepine, as cross-reactivity may occur. Dose adjustments may be necessary in renal or hepatic impairment. Lovax OD 300 should be used under medical supervision with regular monitoring of clinical response and laboratory parameters to ensure optimal therapeutic outcomes and safety.